Next Article in Journal
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer
Next Article in Special Issue
ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients
Previous Article in Journal / Special Issue
Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Cancers 2017, 9(8), 100; doi:10.3390/cancers9080100

Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas

1
Inserm, UMR1037 CRCT, F-31000 Toulouse, France
2
Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
3
CNRS, ERL5294 CRCT, F-31000 Toulouse, France
4
Laboratoire d’Excellence Toulouse Cancer-TOUCAN, F-31024 Toulouse, France
*
Author to whom correspondence should be addressed.
Academic Editor: Raymond Lai
Received: 7 June 2017 / Revised: 4 July 2017 / Accepted: 28 July 2017 / Published: 3 August 2017
(This article belongs to the Special Issue Targeting ALK in Cancer)
View Full-Text   |   Download PDF [240 KB, uploaded 3 August 2017]

Abstract

The discovery of microRNA (miRNA) has provided new and powerful tools for studying the mechanism, diagnosis and treatment of human cancers. The down-regulation of tumor suppressive miRNA by hypermethylation of CpG island (CpG is shorthand for 5′-C-phosphate-G-3′, that is, cytosine and guanine separated by only one phosphate) is emerging as a common hallmark of cancer and appears to be involved in drug resistance. This review discusses the role of miRNA and DNA methylation in drug resistance mechanisms and highlights their potential as anti-cancer therapies in Anaplastic Lymphoma Kinase (ALK)-positive lymphomas. These are a sub-type of non-Hodgkin’s lymphomas that predominantly affect children and young adults and are characterized by the expression of the nucleophosmin (NPM)/ALK chimeric oncoprotein. Dysregulation of miRNA expression and regulation has been shown to affect several signaling pathways in ALK carcinogenesis and control tumor growth, both in cell lines and mouse models. These data suggest that the modulation of DNA methylation and/or the expression of these miRNA could serve as new biomarkers and have potential therapeutic applications for ALK-positive malignancies. View Full-Text
Keywords: epigenetics; DNA methylation; microRNA (miRNA); ALK; lymphomas; biomarkers; novel treatments epigenetics; DNA methylation; microRNA (miRNA); ALK; lymphomas; biomarkers; novel treatments
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hoareau-Aveilla, C.; Meggetto, F. Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas. Cancers 2017, 9, 100.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top